ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1054

Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis

Nina Mars1,2, Anne M Kerola2,3, Markku J Kauppi4,5, Matti Pirinen1, Outi Elonheimo6 and Tuulikki Sokka-Isler7, 1Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 2University of Helsinki, Helsinki, Finland, 3Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4School of Medicine, University of Tampere, Tampere, Finland, 5Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, 6FCG Finnish Consulting Group Ltd., Helsinki, Finland, 7Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: administrative databases, Health Care, Health care cost, outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Utilization patterns in rheumatoid arthritis (RA) are complex. For targeted interventions, patients with special healthcare needs should be recognized. Our aim was to explore healthcare utilization profiles in RA by cluster analysis.

Methods: The RA patients attending Jyväskylä Central Hospital rheumatology unit, Finland, are as of 2007 enrolled prospectively in a structured digital database, from which we identified patients with rheumatology clinic visits in 2012-2014. We combined this clinical data with well-recorded administrative data on fiscal year 2014 on all public healthcare visits, both in primary and specialty care. For each patient, we considered the median of time dependent clinical variables. Clustering variables were disease activity score (DAS28-3), health assessment questionnaire index (HAQ index, 0-3), pain on visual analogue scale (VAS, 0-100) and total annual health services related direct costs (€), excluding out of pocket medication costs. The number of clusters was set based on dendrogram examination. We applied hierarchical clustering with Ward’s minimum variance method with Euclidean distance.

Results: Of 844 patients with RA, complete-case analysis (n = 827) derived four clusters. Descriptive statistics are in Table 1 and distributions for DAS28-3 and HAQ index are in Figure 1. Cluster 1 was the largest cluster constituting relatively young patients with low costs, low disease activity, and minimal disability. Cluster 2 was characterized by high pain levels and disability, despite fairly low average DAS28-3. Compared with cluster 2, patients in cluster 3 had high average disease activity and rheumatic disease -related costs, and biologics were more frequently used. Still, they presented with less pain and disability compared with cluster 2. Cluster 4 was small, heterogeneous and characterized by exceptionally high average costs. These patients had costly and severe comorbidities in addition to RA.

 

Conclusion: Over half of patients had low costs and favorable outcome measures, whereas a fifth was characterized by high disease activity and active treatment of RA, yielding higher costs. Pain and disability did not necessarily relate to high rheumatic disease -related costs. In all clusters, over half of costs were attributable to comorbidities.

 

 

Cluster 1

Cluster 2

Cluster 3

Cluster 4

n

467

147

180

33

Age (mean ± SD)

58.2 ± 15.3

66.5 ± 11.8

63.3 ± 13.9

71.1 ± 10.8

Disease duration (median)

11.8 ± 8.5

16.3 ± 12.6

16.0 ± 12.5

18.6 ± 12.9

Pain (mean ± SD)

15.9 ± 12.2

55.2 ± 18.3

37.2 ± 15.8

47.0 ± 20.9

RF+ (%)

65

71

77

90

Ever biologics (%)

23.3

24.5

43.3

45.5

Number of comorbidities

2.1 ± 2.1

3.7 ± 2.8

3.4 ± 2.5

5.7 ± 3.5

Mean total costs/patient (€)

2367

3785

6772

36206

Mean rheumatic disease costs/patient (%*)

1054 (48.5)

1455 (44.8)

3076 (48.5)

4323 (13.0)

*Of recorded healthcare contacs

Table 1. Descriptive statistics.

 

 

 

 

 

Figure 1. Distributions for DAS28-3 and HAQ index based on individual time dependent medians.

 


Disclosure: N. Mars, None; A. M. Kerola, None; M. J. Kauppi, None; M. Pirinen, None; O. Elonheimo, Finnish Consulting Group Ltd, 3; T. Sokka-Isler, None.

To cite this abstract in AMA style:

Mars N, Kerola AM, Kauppi MJ, Pirinen M, Elonheimo O, Sokka-Isler T. Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/healthcare-utilization-profiles-in-rheumatoid-arthritis-a-cluster-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-utilization-profiles-in-rheumatoid-arthritis-a-cluster-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology